The enzyme dipeptidyl peptidase-4 (DPP-4 ... the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are orally active and increase ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

In patients with type 2 diabetes, the risk for chronic kidney disease differed among users of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylurea.

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome ...

It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis ... than the industry average, reaching 4.03. This indicates a heavier reliance on ...

Dipeptidyl peptidase-4 (DPP-4) inhibitors Janumet XR, Onglyza Blocks the enzymes which break down hormones (incretin) that signal the pancreas to make insulin. Also slows digestion and the release ...

Dipeptidyl peptidase-4 (DPP-4) is an enzyme that destroys hormones called incretins. These hormones help the body produce ...